• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Novartis launches affordable medicines portfolio

Novartis launches affordable medicines portfolio

September 24, 2015
CenterWatch Staff

Novartis has launched Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries. The portfolio addresses cardiovascular diseases, diabetes, respiratory illnesses and breast cancer and will be offered to governments, non-governmental organizations (NGOs) and other public-sector healthcare providers for $1 per treatment, per month.

The Novartis Access portfolio includes patented and generic Novartis medicines. It will be launched first in Kenya, Ethiopia and Vietnam. Over the coming years, Novartis plans to roll out Novartis Access to 30 countries, depending on demand.

The products included in the Novartis Access product portfolio have been selected based on the World Health Organization's Essential Medicines List and are among the most commonly prescribed medicines in these countries. Novartis expects this new approach to be commercially sustainable over the long term, enabling continuous support in those regions.

Each year, about 28 million people die from chronic noncommunicable diseases (NCDs) in low- and middle-income countries, representing 75% of deaths from NCDs globally. By 2025, the WHO projects that 75% of all deaths will be due to NCDs, mostly due to the rapid increase of NCDs in poverty-stricken areas.

Novartis is launching Novartis Access to coincide with the United Nations Sustainable Development Summit 2015, where the new Sustainable Development Goals will be adopted.

To more effectively address the rapid rise of chronic diseases in low- and low-middle-income countries, Novartis is actively seeking to partner with governments, NGOs and other public-sector organizations to strengthen healthcare systems. Areas of potential collaboration include programs to raise awareness about diseases, train healthcare workers to diagnose and treat chronic illnesses and strengthen medicine distribution systems.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing